      Document 0084
 DOCN  DRG0084
 UNIQUE IDENTIFIER        DRG-0163
 NAME OF SUBSTANCE        Wobenzym [Oncology 1990;47(6)]
 REGISTRY NUMBER          72506-65-1
 STANDARD CHEMICAL NAME   Wobenzym [CHEMLINE]
 PROTOCOL ID NUMBERS      FDA 122A
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: In vitro treatment of human
                          PBMNC with proteolytic enzymes (bromelain,
                          papain) and amylase leads to production of
                          large amounts of tumor necrosis factor-alpha
                          (TNF-alpha), interleukin-1-beta (IL-1 beta)
                          and interleukin-6 (IL-6) in a time and dose
                          dependent manner. A commercial mixture of
                          these enzymes (Wobenzym) showed similar
                          effects. Intact bromelain, papain or amylase,
                          which are components of Wobenzym, induce
                          cytokine production in peripheral blood
                          mononuclear cells (PBMNC) in vitro. IFN-alpha
                          (interferon alpha) and IFN-gamma, which had
                          no effect alone, synergistically increased
                          TNF (tumor necrosis factor) production when
                          applied together with the enzymes. After
                          ingestion of milligram doses of the
                          polyenzyme preparation, the PBMNC of healthy
                          volunteers acquire the ability to produce
                          TNF-alpha, IL (interleukin)-1 beta and IL-6.
                          This may explain the antitumor effects of
                          such enzymes. The polyenzyme preparation also
                          may have strong immunomodulary effects in
                          combination with IFN-gamma. [Cancer Biother
                          1994 Fall;9(3)] [Oncology 1993;50(6)]
 DISEASES STUDIED/TREATED Enhancement of immune function in HIV
                          infection [FDA 122A]
 CLASSIFICATION CODE      Immunomodulator [Oncology 1993;50(6)]
 OTHER MAJOR USES         Nutritional supplement given with
                          phytotherapy for cancer; treatment of
                          rheumatoid arthritis; adjuvant treatment for
                          postoperative pain [Schweiz Rundsch Med Prax
                          May 29 1990; 79(22)] [Z Rheumatol 1985
                          Mar-Apr;44(2)] [Anaesthesist 1993;42(12)]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: A polyenzyme preparation
                          composed of different enzymes and coenzymes
                          extracted from animal and plant tissues
                          [Oncology 1990;47(6)] [MeSH]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Consisting of a combination
                          of pancreatin, bromelains, papayotin, lipase,
                          amylase, trypsin, chymotrypsin, and rutin
                          [Oncology 1990;47(6)] [MeSH]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: Tablets. [FDA 122A]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Oral. [FDA 122A]
 MANUFACTURERS            Mucos Pharma GmbH and Company
 REFERENCES               Zavadova E, Desser L, Mohr T. Stimulation of
                          reactive oxygen species production and
                          cytotoxicity in human neutrophils in vitro
                          and after oral administration of a polyenzyme
                          preparation. Cancer Biother 1995
                          Summer;10(2):147-52.
 REFERENCES               Desser L, Rehberger A, Kokron E, Paukovits W.
                          Cytokine synthesis in human peripheral blood
                          mononuclear cells after oral administration
                          of polyenzyme preparations. Oncology 1993
                          Nov-Dec;50(6):403-7.
 REFERENCES               Sakalova A, Mikulecky M, Holomanova D,
                          Langner D, Ransberger K, Stauder G, Mistrik
                          M, Gazova S, Chabronova I, Benzova M, et al.
                          [The favorable effect of hydrolytic enzymes
                          in the treatment of immunocytomas and
                          plasmacytomas]. Vnitr Lek 1992
                          Sep;38(9):921-9.
 REFERENCES               Kullich W, Schwann H. [Circulating immune
                          complexes and complement fragment iC3b in
                          chronic polyarthritis during 12 months
                          therapy with oral enzymes in comparison with
                          oral gold.] Wien Med Wochenschr
                          1992;142(22):493-7.
 REFERENCES               Desser L, Rehberger A. Induction of tumor
                          necrosis factor in human peripheral-blood
                          mononuclear cells by proteolytic enzymes.
                          Oncology 1990;47(6):475-7.
 ENTRY MONTH              9302
 LAST REVISION DATE       960310
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
